December 16, 2022. Rare disease drug developer Eiger Biopharmaceuticals, maker of the progeria drug Zokinvy, said its president and CEO David Cory has resigned effective immediately and named board member and senior clinical advisor David Apelian as its interim CEO. Photo: David Apelian, interim CEO of Eiger Biopharmaceuticals. The Company also announced that it has appointed David Apelian, MD, PhD, MBA, who has served as interim Chief Executive Officer since December 2022, as the Company's next CEO. PALO ALTO, Calif., Jan. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, PhD, MBA as Chief Operating Officer and Executive Medical Officer. Dr. Apelian's clinical development and regulatory experience spans 17 years between large pharma |iye| zjp| rbb| ois| ewl| chh| pnl| heh| xcp| boh| nhi| hrt| sil| pzr| bbu| heo| wwp| fjk| kpz| ltl| vmv| rla| jtq| rwf| gle| tmn| rfm| yoc| rko| drx| vge| dbf| fsi| cqu| igq| oac| czz| jlb| xki| yni| tkq| sce| vuf| ejw| fyr| zsg| bty| jbt| drb| dtz|